Proactiveinvestors United Kingdom RNS press releases https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom RNS press releases RSS feed en Fri, 06 Dec 2019 20:47:09 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Lynparza approved in China for 1L BRCAm ovarian ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191205070013_14336003 Thu, 05 Dec 2019 07:00:13 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191205070013_14336003 <![CDATA[RNS press release - AstraZeneca divests Seroquel rights: US and Canada ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191203070010_14332137 Tue, 03 Dec 2019 07:00:10 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191203070010_14332137 <![CDATA[RNS press release - Block listing Interim Review ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191202150004_14331503 Mon, 02 Dec 2019 15:00:04 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191202150004_14331503 <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191202150004_14331502 Mon, 02 Dec 2019 15:00:04 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191202150004_14331502 <![CDATA[RNS press release - Imfinzi granted FDA Priority Review for SCLC ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191129070004_14328194 Fri, 29 Nov 2019 07:00:04 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191129070004_14328194 <![CDATA[RNS press release - Calquence approved in CLL in the US ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191121181504_14318609 Thu, 21 Nov 2019 18:15:04 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191121181504_14318609 <![CDATA[RNS press release - Qtrilmet approved in the EU for treatment of T2D ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191115070003_14309217 Fri, 15 Nov 2019 07:00:03 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191115070003_14309217 <![CDATA[RNS press release - FDA accepts regulatory submission for selumetinib ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191114070008_14307370 Thu, 14 Nov 2019 07:00:08 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191114070008_14307370 <![CDATA[RNS press release - Anifrolumab demonstrated superiority in TULIP 2 ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191112070012_14303703 Tue, 12 Nov 2019 07:00:12 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191112070012_14303703 <![CDATA[RNS press release - Roxadustat pooled analyses: no increased CV risk ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191111070007_14301823 Mon, 11 Nov 2019 07:00:07 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191111070007_14301823 <![CDATA[RNS press release - Roxadustat significantly increased haemoglobin ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191108070002_14299859 Fri, 08 Nov 2019 07:00:02 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191108070002_14299859 <![CDATA[RNS press release - Calquence data to show improved progression-free ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191106141057_14297271 Wed, 06 Nov 2019 14:10:57 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191106141057_14297271 <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191101150005_14291446 Fri, 01 Nov 2019 15:00:05 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191101150005_14291446 <![CDATA[RNS press release - AstraZeneca divests rights to Seroquel and ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191030070003_14285678 Wed, 30 Oct 2019 07:00:03 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191030070003_14285678 <![CDATA[RNS press release - Imfinzi and Imfinzi plus tremelimumab delayed ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191028153144_14283566 Mon, 28 Oct 2019 15:31:44 +0000 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191028153144_14283566 <![CDATA[RNS press release - AstraZeneca year-to-date and Q3 2019 results ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191024070005_14278212 Thu, 24 Oct 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191024070005_14278212 <![CDATA[RNS press release - Farxiga approved in the US to reduce the risk of ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191021070007_14272750 Mon, 21 Oct 2019 07:00:07 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191021070007_14272750 <![CDATA[RNS press release - Trastuzumab deruxtecan granted FDA Priority Review ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191017070005_14269194 Thu, 17 Oct 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191017070005_14269194 <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191004150403_14255130 Fri, 04 Oct 2019 15:04:03 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191004150403_14255130 <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191004150003_14255116 Fri, 04 Oct 2019 15:00:03 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20191004150003_14255116